Mexidol: Instructions for use: Description of the drug: Price for EUROLAB

Write a review

Reviews: 0

Manufacturers: Armavir biofactory, Ellara MC, RKNPK Rosmedtekhnologii

Active ingredients

Ethylmethylhydroxypyridine succinate

Disease class

Mild cognitive impairment
Post-concussion syndrome
Mental and behavioral disorders caused by alcohol consumption - withdrawal state
Anxiety disorder, unspecified
Transient transient cerebral ischemic attacks [attacks] and related syndromes
Autonomic nervous system disorders
Toxic encephalopathy
Encephalopathy, unspecified
Brain infarction
Hypertensive encephalopathy
Cerebrovascular disease, unspecified
State of emotional shock and stress, unspecified
Malaise and fatigue
Intracranial trauma
Consequences of intracranial injury
Antipsychotic and neuroleptic drugs

Clinical and pharmacological group

Not indicated. See instructions

Pharmacological action

Antioxidant

Pharmacological group

Means for correcting disorders of alcoholism, toxicity and drug addiction
Antihypoxants and antioxidants

Solution for injection Mexidol (Mexidolum)

Instructions for medical use of the drug

Description of pharmacological action

Indications for use

- acute cerebrovascular accidents; — TBI, consequences of TBI; - encephalopathy; — vegetative dystonia syndrome; — mild cognitive disorders of atherosclerotic origin; - anxiety disorders in neurotic and neurosis-like conditions; — relief of withdrawal syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders; - acute intoxication with antipsychotic drugs; - acute purulent-inflammatory processes in the abdominal cavity (acute necrotizing pancreatitis, peritonitis) - as part of complex therapy.

Release form

Solution for injection 5% 1 amp. Mexidol in 2 ml ampoules, 5 ampoules in a blister pack; in a cardboard pack 2 packs. Solution for injection 1 amp. Mexidol 50 mg in ampoules of 2 or 5 ml, in a blister pack 5 ampoules; in a cardboard pack 2 packs.

Pharmacodynamics

Mexidol has antihypoxic, membrane protective, nootropic, anticonvulsant, anxiolytic effects, and increases the body's resistance to stress. The drug increases the body's resistance to the effects of major damaging factors, to oxygen-dependent pathological conditions (shock, hypoxia and ischemia, cerebrovascular accident, intoxication with alcohol and antipsychotic drugs - antipsychotics). Mexidol improves cerebral metabolism and blood supply to the brain, microcirculation and rheological properties of blood, and reduces platelet aggregation. Stabilizes the membrane structures of blood cells (erythrocytes and platelets) during hemolysis. It has a hypolipidemic effect, reduces the level of total cholesterol and LDL. Reduces enzymatic toxemia and endogenous intoxication in acute pancreatitis. The mechanism of action of Mexidol is due to its antihypoxic, antioxidant and membrane protective effects. It inhibits the processes of lipid peroxidation, increases the activity of superoxide oxidase, increases the lipid-protein ratio, reduces the viscosity of the membrane, and increases its fluidity. Modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, helps preserve the structural and functional organization of biomembranes, improves the transport of neurotransmitters and synaptic transmission. Mexidol increases dopamine levels in the brain. Causes an increase in the compensatory activity of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions, with an increase in the content of ATP, creatine phosphate and activation of the energy-synthesizing functions of mitochondria, stabilization of cell membranes.

Pharmacokinetics

When administered intramuscularly, the drug is detected in the blood plasma for 4 hours after administration. Cmax when administered in doses of 400–500 mg is 3.5–4.0 mcg/ml, Tmax is 0.45–0.50 hours. Mexidol quickly passes from the bloodstream into organs and tissues and is quickly eliminated from the body. The drug retention time (MRT) is 0.7–1.3 hours. Mexidol is excreted from the body in the urine, mainly in glucurone-conjugated form and in small quantities unchanged.

Use during pregnancy

Contraindicated during pregnancy. During treatment, breastfeeding should be stopped (adequate and strictly controlled clinical studies of the safety of the drug Mexidol during pregnancy and breastfeeding have not been conducted).

Contraindications for use

- increased individual sensitivity to the drug; - acute renal dysfunction; - acute dysfunction of the liver. Strictly controlled clinical studies of the safety of the drug Mexidol in children, pregnancy and breastfeeding have not been conducted.

Side effects

Nausea and dry mouth, drowsiness, and allergic reactions may occur.

Directions for use and doses

IM or IV (stream or drip). For intravenous administration, water for injection is used as a solvent. Mexidol is administered in a stream over 5–7 minutes, and dropwise at a rate of 60 drops per minute. Doses are selected individually. Begin treatment with a dose of 0.05–0.1 g 1–3 times a day, gradually increasing the dose until a therapeutic effect is obtained. The duration of treatment and the choice of individual dose depend on the severity of the patient’s condition and the effectiveness of treatment. The maximum daily dose should not exceed 0.8 g. For the treatment of atherosclerotic dementia in elderly patients, Mexidol is prescribed IM at a dose of 0.1–0.3 g/day. In case of acute intoxication with neuroleptics, the drug is administered into a vein at a dose of 0.5–0.3 g/day. In the complex treatment of acute purulent-inflammatory processes of the abdominal cavity (acute destructive pancreatitis, peritonitis), Mexidol is prescribed in a single dose of 200 mg 3 times a day. In case of severe disease, the drug is diluted in 200 ml of physiological 0.9% sodium chloride solution and administered at a rate of 40–60 drops per minute. For milder cases of the disease, Mexidol is administered intramuscularly. The course of treatment is 3–10 days.

Overdose

In case of overdose, drowsiness may develop.

Interactions with other drugs

Enhances the effect of benzodiazepine anxiolytics (phenazepam, diazepam), anticonvulsants (carbamazepine) and antiparkinsonian drugs (levodopa). Reduces the toxic effects of ethyl alcohol.

Precautions for use

Patients with blood pressure above 180/100 mmHg, a crisis course of arterial hypertension and severe affective instability require careful monitoring of blood pressure during Mexidol therapy. Use with caution while working for vehicle drivers and people whose profession involves increased concentration.

Special instructions for use

In some cases, especially in predisposed patients with bronchial asthma with increased sensitivity to sulfites, severe hypersensitivity reactions may develop.

Storage conditions

List B.: In a place protected from light.

Best before date

24 months

ATX classification:

N Nervous system

N07 Other drugs for the treatment of diseases of the nervous system

N07X Other drugs for the treatment of diseases of the nervous system

N07XX Other drugs for the treatment of diseases of the nervous system

MEXIDOL solution for injection. IV, IM 50 mg/ml amp. 5 ml No. 10

Directions for use and doses

IM or IV (stream or drip).
When administered by infusion, the drug should be diluted in 0.9% sodium chloride solution.

Mexidol is administered in a stream slowly over 5-7 minutes, drip-wise at a rate of 40-60 drops per minute. The maximum daily dose should not exceed 1200 mg.

For acute cerebrovascular accidents

Mexidol is used in the first 10-14 days - 200-500 mg IV drip 2-4 times a day, then 200-250 mg IM 2-3 times a day for 2 weeks.

For traumatic brain injury and consequences of traumatic brain injury

Mexidol is used for 10-15 days intravenously, 200-500 mg 2-4 times a day.

For dyscirculatory encephalopathy in the decompensation phase

Mexidol should be prescribed intravenously in a stream or drip at a dose of 200-500 mg 1
-
2 times a day for 14 days. Then IM 100-250 mg/day. over the next 2 weeks.

For course prophylaxis of dyscirculatory encephalopathy

the drug is administered intramuscularly at a dose of 200-250 mg 2 times a day for 10-14 days.

For mild cognitive impairment in elderly patients and anxiety disorders

the drug is used intramuscularly at a daily dose of 100-300 mg/day for 14-30 days.

In acute myocardial infarction as part of complex therapy

Mexidol is administered intravenously or intramuscularly for 14 days, against the background of traditional therapy for myocardial infarction, including nitrates, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, thrombolytics, anticoagulant and antiplatelet agents, as well as symptomatic agents according to indications.

In the first 5 days, to achieve maximum effect, it is advisable to administer the drug intravenously; in the next 9 days, Mexidol can be administered intramuscularly. Intravenous administration of the drug is carried out by drip infusion, slowly (to avoid side effects) in a 0.9% sodium chloride solution or 5% dextrose (glucose) solution in a volume of 100-150 ml for 30-90 minutes. If necessary, a slow jet injection of the drug, lasting at least 5 minutes, is possible.

The drug is administered (intravenous or intramuscular) 3 times a day, every 8 hours. The daily therapeutic dose is 6-9 mg/kg body weight per day, a single dose is 2-3 mg/kg body weight. The maximum daily dose should not exceed 800 mg, single dose - 250 mg.

For open-angle glaucoma of various stages as part of complex therapy

Mexidol is administered intramuscularly at 100-300 mg/day, 1-3 times a day for 14 days.

For alcohol withdrawal syndrome

Mexidol is administered in a dose of 200-500 mg intravenously or intramuscularly 2-3 times a day for 5-7 days.

In case of acute intoxication with antipsychotic drugs

the drug is administered intravenously at a dose of 200-500 mg/day for 7-14 days.

In acute purulent-inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis)

the drug is prescribed on the first day both in the preoperative and postoperative periods. The administered doses depend on the form and severity of the disease, the prevalence of the process, and variants of the clinical course. The drug should be discontinued gradually only after a stable positive clinical and laboratory effect.

For acute edematous (interstitial) pancreatitis

Mexidol is prescribed 200-500 mg 3 times a day, intravenously (in 0.9% sodium chloride solution) and intramuscularly.

Mild severity of necrotizing
pancreatitis
- 100-200 mg 3 times a day intravenously (in 0.9% sodium chloride solution) and intramuscularly.

Moderate severity

- 200 mg 3 times a day, intravenously (in 0.9% sodium chloride solution).

Severe course

— in a pulse dosage of 800 mg on the first day, with a double administration regimen, then 200-500 mg 2 times a day with a gradual reduction in the daily dose.

Extremely severe course

- at an initial dosage of 800 mg/day until the manifestations of pancreatogenic shock are persistently relieved, upon stabilization of the condition, 300-500 mg 2 times a day intravenously (in 0.9% sodium chloride solution) with a gradual decrease in the daily dosage.

Similar drugs:

Succinic acid Substance-powder
Neurotropin (neurotrophin) Solution for injection
Thiotriazoline Solution for intravenous and intramuscular administration
Picamilon (Picamilonum) Oral tablets
Heptral Lyophilisate for the preparation of a solution for intramuscular, subconjunctival administration and for instillation into the eye
Vitamin E Capsule
Ascozin Chewable tablets
Dialipon Capsule
Mexiprim Oral tablets
Neurolipon Capsule

** The Drug Directory is intended for informational purposes only. For more complete information, please refer to the manufacturer's instructions. Do not self-medicate; Before starting to use the drug Mexidol, you should consult a doctor. EUROLAB is not responsible for the consequences caused by the use of information posted on the portal. Any information on the site does not replace medical advice and cannot serve as a guarantee of the positive effect of the drug.

Are you interested in the drug Mexidol? Do you want to know more detailed information or do you need a doctor's examination? Or do you need an inspection? You can make an appointment with a doctor - the Euro lab is always at your service! The best doctors will examine you, advise you, provide the necessary assistance and make a diagnosis. You can also call a doctor at home . Euro lab clinic is open for you around the clock.

** Attention! The information presented in this medication guide is intended for medical professionals and should not be used as a basis for self-medication. The description of the drug Mexidol is provided for informational purposes and is not intended for prescribing treatment without the participation of a doctor. Patients need to consult a specialist!

If you are interested in any other drugs and medications, their descriptions and instructions for use, information about the composition and form of release, indications for use and side effects, methods of use, prices and reviews of drugs, or you have any other questions and suggestions - write to us, we will definitely try to help you.